IndraLab

Statements

Pazopanib inhibits RIPK1. 7 / 9
2 | 1 6
reach
"Interestingly, some US Food and Drug Administration-approved anticancer drugs, including ponatinib and pazopanib, can inhibit RIPK1; these drugs would be better prospects in further clinical studies (Fauster et al., 2015)."
34594225
reach
"Moreover, some FDA-approved drugs, including sorafenib, pazopanib, and regorafenib, have been shown to inhibit RIPK1 and/or RIPK3 in an off-target manner ."
37741898
reach
"Furthermore, ponatinib and pazopanib are expected to suppress the activity of receptor-interacting serine/threonine protein kinase 1 (RIPK1), a SARS-CoV-2 NSP12 interactor linked to apoptosis, necroptosis, and inflammatory processes [167]."
36252792
reach
"Ponatinib and pazopanib, which were found could inhibit RIP1 and RIP3, has been approved by Food and Drug Administration (FDA) as chemotherapeutics in clinical treatment [22] ."
37421775
eidos
"In addition , the activity of RIPK1 , an NSP12 interactor which is associated with apoptosis , necroptosis , and inflammatory pathways , is predicted to be inhibited by ponatinib and pazopanib ."
32444466
reach
"Mechanism study showed that ponatinib inhibits both RIPK1 and RIPK3, while pazopanib preferentially inhibits RIPK1."
29426003
reach
"Two receptor tyrosine kinase inhibitors, Pazopanib and Ponatinib were confirmed to block cell necroptosis by targeting RIPK1, but failed to apply in clinic trails due to cardiotoxicity ( Fauster et al[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
35988837